The placebo group had an 88% rate at four years. Longer-term follow-up, including overall survival, is continuing.
Trial Links Darolutamide Add-On to 95% Four-Year Metastasis-Free Survival
The placebo group had an 88% rate at four years. Longer-term follow-up, including overall survival, is continuing.